• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sage Therapeutic Com (NQ: SAGE )

    7.900 -0.210 (-2.59%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 511,861
    Open 8.000
    Bid (Size) 7.500 (2)
    Ask (Size) 8.390 (3)
    Prev. Close 8.110
    Today's Range 7.775 - 8.120
    52wk Range 7.700 - 28.26
    Shares Outstanding 59,762,106
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
    From Sage Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -64.86%
    -64.86%
    1 Month
    -26.92%
    -26.92%
    3 Month
    -33.78%
    -33.78%
    6 Month
    -65.21%
    -65.21%
    1 Year
    -60.38%
    -60.38%

    More News

    Read More
    Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts
    Via Benzinga
    Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Analyst Expectations For Sage Therapeutics's Future
    Via Benzinga
    19 Analysts Have This To Say About Sage Therapeutics
    Via Benzinga
    Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
    Via Benzinga
    Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
    Via Investor's Business Daily
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
    From Sage Therapeutics, Inc.
    Via Business Wire
    Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
    From Sage Therapeutics, Inc.
    Via Business Wire
    Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Sage Therapeutics Reports Phase 2 Huntington's Data
    Via Benzinga
    Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
    From Sage Therapeutics
    Via Business Wire
    Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Sage Therapeutics, Inc.
    Via Business Wire
    Wall Street's Top 10 Stock Calls This Week - Sunday, June 2
    Via Talk Markets
    Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
    Via Benzinga
    Sage Therapeutics to Participate in Upcoming May Investor Conferences
    From Sage Therapeutics
    Via Business Wire
    SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
    From Sage Therapeutics, Inc.
    Via Business Wire
    Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.